Refine by
Tumor Microenvironment Equipment & Supplies In Iran
39 equipment items found
by:Onegene Biotechnology based inSuwon, SOUTH KOREA
OGB23501 is a first-in-class tri-specific tumor microenvironment (TME) immune activator, which simultaneously targets PD-1, CTLA-4, and VEGF. We aim to develop it as a potential backbone therapy for melanoma, NSCLC, HCC, and renal ...
Manufactured by:PharmAbcine Inc. based inYuseong-gu, SOUTH KOREA
PMC-402 is a monoclonal antibody that targets the human TIE2 that regulated activation, proliferation, and repolarization of Tie2 expressing macrophages, resulting in T cell activation. It binds to TIE2 expressing macrophages that activate T cells in the tumor microenvironment ...
Manufactured by:Senti Biosciences based inSouth San Francisco, CALIFORNIA (USA)
The product profile of SENTI-301 has the potential to promote expansion and persistence of NK cells, and activate and recruit the body’s own immune cells into the solid tumor microenvironment for enhanced anti-tumor activity. ...
Manufactured by:Eutilex Co.,Ltd. based inSeoul, SOUTH KOREA
Fully humanized therapeutic monoclonal antibody. This could convert type II macrophage to Type I. Anti-tumor efficacy of the antibody can be achieved by modulating tumor ...
Manufactured by:PharmAbcine Inc. based inYuseong-gu, SOUTH KOREA
It binds to TIE2 expressing endothelial cells and normalize VEGF-induced pathological leaky blood vessels in eyes and TME (tumor ...
Manufactured by:Sigma-Aldrich based inBellefonte, PENNSYLVANIA (USA)
SynTumor is a 3D tissue model for real-time visualization and quantitative assessment of cell-cell and cell-drug interactions in a physiologically and morphologically realistic tumor ...
Manufactured by:NanoString based inSeattle, WASHINGTON (USA)
The GeoMx Immune Pathways Panel is designed for targeted profiling of the tumor, tumor microenvironment, and tumor immune status. Profile up to 96 RNA targets with spatial resolution from a single tissue section using the GeoMx Digital Spatial Profiler ...
Manufactured by:Tonix Pharmaceuticals Holding Corp. based inChatham, NEW JERSEY (USA)
TFF2 is also expressed at low levels in splenic immune cells and is now appreciated to have intravascular roles in spleen and in the tumor microenvironment. In gastric cancer, TFF2 is epigenetically silenced, and TFF2 is suggested to be protective against cancer development through several ...
Manufactured by:Veracyte based inMarseille Cedex 9, FRANCE
Veracyte offers a unique multiplex tissue imaging and analysis approach combining multiple technologies perfectly adapted to the comprehensive characterization of the tumor microenvironment. ...
Manufactured by:MedGenome Inc. based inCounty of New Castle, DELAWARE (USA)
OncoPeptTUME — A novel in-silico approach to model the tumor microenvironment and predict treatment efficacy and long-term survival benefits for immunotherapy applications. Cancer immunotherapy is now established as a major therapeutic modality. Cancer immunotherapy drugs elicit their anti-tumor immune response in a subset of the treated ...
by:GI Innovation based inSeoul, SOUTH KOREA
Promotes the generation of cancer-specific effector T cell (Teff) in lymph nodes, and induces the activation and proliferation of tumor-infiltrating Teff and NK cells. Controls the immuno-suppressive function of regulatory T cells (Tregs) in tumor microenvironment (TME). Restores T cell function and anti-cancer immune responses in TME. Secures ...
Manufactured by:PsiOxus Therapeutics Ltd. based inAbingdon, UNITED KINGDOM
Our clinically validated T-SIGn® viral vector platform delivers multiple transgene payloads that re-program the tumor microenvironment of both primary and metastatic tumors. Our platform can integrate rationally designed synthetic agents to unleash the power of the immune system, including genetically engineered cell ...
by:Zymeworks Inc based inVancouver, BRITISH COLUMBIA (CANADA)
in a single, transferable, conditionally active design. Right Place at the Right Time. With PROgrammed Tumor Engagement & Checkpoint/Co-stimulation Targeting, the ProTECT platform delivers multifunctional tumor-specific activity while simultaneously enhancing immune modulation through the conditional activity of a natural immunomodulatory pair such as ...
by:Pure Biologics SA based inWroclaw, POLAND
The PB003 (PureActivator) project embraces a novel approach, aiming to develop a drug based on a bimodal fusion protein, which synergistically activates NK cells and minimizes immunosuppression in the lung cancer tumor ...
Manufactured by:Elpiscience based inShanghai, CHINA
ES014 is a first-in-class anti-CD39xTGF-β bispecific antibody (bsAb) that simultaneously targets the adenosine and TGF-β pathways, two major immunosuppressive mechanisms in the tumor microenvironment (TME). Solid tumors frequently express TGF-β, which suppresses T cell activation and induces CD39 expression, the rate-limiting ...
by:Pure Biologics SA based inWroclaw, POLAND
TNBC can be further categorized into three types: Type 1 (also known as the “cold” type) is characterized by a tumor with low infiltration of immune cells into the tumor microenvironment; Type 2 is characterized by inactive cells of the innate immune system; Type 3 (also known as the “hot” type) is characterized by an ...
Manufactured by:Ibio, Inc. based inBryan, TEXAS (USA)
Advances in the field of immuno-oncology have led to new and better treatment outcomes for a range of cancers, and particularly, blood cancers. However, even with the advent of checkpoint inhibitors as immunotherapies for solid tumors, significant challenges remain. This is in part due to dynamics in the tumor microenvironment, wherein regulatory ...
Manufactured by:PsiOxus Therapeutics Ltd. based inAbingdon, UNITED KINGDOM
Three transgenes: Producing membrane bound CD80 and secreted MIP1α and IFNa. As part of our expanding T-SIGn platform pipeline, this candidate is progressing through its IND enabling activities in readiness for entering clinical ...
Manufactured by:PsiOxus Therapeutics Ltd. based inAbingdon, UNITED KINGDOM
Three transgenes: Producing IL-12, IL-15 and a chemokine. As part of our expanding T-SIGn platform pipeline, this candidate is progressing through its IND enabling activities in readiness for entering clinical ...
Manufactured by:PsiOxus Therapeutics Ltd. based inAbingdon, UNITED KINGDOM
Novel transgene combinations. Our research team are developing a suite of viral vectors with new and innovative transgene ...